Science

Galip Can Uyar: The Phase 3 CONTACT-02 Trial

Collage photo of Galip Can Uyar and Neeraj Agarwal

Jul 2, 2025, 09:11

Galip Can Uyar: The Phase 3 CONTACT-02 Trial

Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X about a paper by Neeraj Agarwal et al. published in The Lancet Oncology:

“BREAKING in mCRPC

Published in The Lancet Oncology (July 2025)

The phase 3 CONTACT-02 trial shows:

Cabozantinib + Atezolizumab significantly improves PFS over second ARPI (6.3 vs 4.2 months; HR: 0.65, p=0.0007)

But no OS benefit was observed (14.8 vs 15.0 months; HR: 0.89)

ORR: 13% vs 6%, DCR: 72% vs 53%

A novel AR-independent combo, especially promising for patients with poor prognosis extrapelvic soft tissue metastases.”

Title: Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

Authors: Neeraj Agarwal, Arun A Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S Merseburger, Andrey Soares, Bradley A McGregor, Bogdan Zurawski, Marinos Tsiatas, Scott North, Igor Bondarenko, Margarita Alfie, Evangelos Bournakis, Lorenzo Antonuzzo, Lena Evilevitch, Andrew Simmons, Fong Wang, Roberta Ferraldeschi, Prachi Nandoskar, Sumanta K Pal.

You can read the Full Article in The Lancet Oncology.

Galip Can Uyar: The Phase 3 CONTACT-02 Trial

More posts featuring Galip Can Uyar.

Andrew Simmons Andrey Soares Arun A. Azad atezolizumab Axel S. Merseburger Bogdan Zurawski Bradley A. McGregor Cabozantinib cancer CONTACT-02 Evangelos Bournakis Fong Wang Fred Saad Galip Can Uyar Igor Bondarenko Joan Carles Lena Evilevitch Lorenzo Antonuzzo Margarita Alfie Marinos Tsiatas mCRPC Neeraj Agarwal Nobuaki Matsubara OncoDaily Oncology Prachi Nandoskar prostate cancer Roberta Ferraldeschi Scott North Stephane Oudard Sumanta K. Pal The Lancet Oncology

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer